Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals

Author:

Alswat Khalid1ORCID,Al-Sohaibani Fahad2,Khathlan Abdullah13,Bashmail Ahmad1,Alanazi Mohammed1,Kurdi Amr4,Almakadma Abdul Hakim5,Al-hamoudi Waleed1

Affiliation:

1. From the Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University, Saudi Arabia

2. From the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

3. From the Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia

4. From the Department of Medicine, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia

5. From the College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Abstract

BACKGROUND: Clearance of hepatitis C virus (HCV) can potentially slow or reverse liver fibrosis and cirrhosis. Studies of fibrosis changes after treatment with direct-acting antivirals (DAAs) are limited. OBJECTIVES: We aimed to assess the impact of DAAs on fibrosis in HCV treatment responders. DESIGN: Retrospective cohort study. SETTING: Tertiary care centers. PATIENTS AND METHODS: This study included adult patients who received DAA treatment for HCV (naïve and experienced) from June 2015 to January 2019 who were treatment responders. Biochemical and hematological data and noninvasive fibrosis markers were recorded at baseline and follow-up. MAIN OUTCOME MEASURES: Aspartate aminotransferase/platelet ratio index (APRI), fibrosis-4 score (FIB-4) and liver stiffness measurements (LSM) at baseline and follow-up. SAMPLE SIZE AND CHARACTERISTICS: 172 HCV treatment responders, mean (SD) age 54.1 (14.1) and body mass index 28.8 (6.5) kg/m 2 at baseline; 96 (55.8%) were females. RESULTS: Fifty-eight (33.7%) patients were HCV treatment-experienced. Most patients were genotype 4 (n=125, 73%) and the mean follow-up was 141 (57.9) weeks. Compared with baseline, changes in alanine aminotransferase ( P <.001), aspartate aminotransferase ( P <.001), and albumin ( P =.01) were statistically significant. Changes in LSM (15.09 kPa [11.4] vs. 10.19 kPa [7.4], P <.001), APRI (0.81 [0.7] vs. 0.34 [0.2], P <.001), and FIB-4 (1.99 [1.4) vs.1.35 [0.9], P <.001), and AST/ALT ratio (0.86 [0.32] vs. 0.95 [0.41], P =.015) were statistically significant. Differences in many of the same parameters were statistically significant between patients with low fibrosis (F0-F1) (n=59, 34.3%) and significant fibrosis (≥F2) (n=113, 65.7%). CONCLUSIONS: Our findings confirm that clearance of HCV with DAAs is associated with significant improvement in fibrosis as assessed by noninvasive liver fibrosis measures, which supports the concept of post-treatment fibrosis regression. Long follow-up studies are needed to assess the impact on morbidity and mortality. LIMITATIONS: Absence of histological correlation with these noninvasive scores. No assessment of fibrosis changes based on HCV geno-type or treatment regimen. CONFLICT OF INTEREST: None.

Publisher

King Faisal Specialist Hospital and Research Centre

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3